Rare monogenic diseases affect millions worldwide; although over 4500 rare disease genotypes are known, diseasemodifying drugs are available for only 5% of them. The sheer number of these conditions combined with their rarity precludes traditional costly drug discovery programs. An economically viable alternative is to repurpose established drugs for rare diseases. Many genetic diseases result from increased or decreased protein activity and identification of clinically approved drugs which moderate this pathogenic dosage holds therapeutic potential. To identify such agents for neurogenetic diseases, we have generated genome-wide transcriptome profiles of mouse primary cerebrocortical cultures grown in the presence of 218 blood-brain barrier (BBB) penetrant clinic-tested drugs. RNAseq and differential expression analyses were used to generate transcriptomic profiles; therapeutically relevant drug-gene interactions related to rare neurogenetic diseases identified in this fashion were further analyzed by quantitative reverse transcriptase-polymerase chain reaction, western blot and immunofluorescence. We have created a transcriptome-wide searchable database for easy access to the gene expression data resulting from the cerebrocortical drug screen (Neuron Screen) and have mined this data to identify a novel link between thyroid hormone and expression of the peripheral neuropathy associated gene Pmp22. Our results demonstrate the utility of cerebrocortical cultures for transcriptomic drug screening, and the database we have created will foster further discovery of novel links between over 200 clinic-tested BBB penetrant drugs and genes related to diverse neurologic conditions.
Introduction
Rare diseases caused by single-gene mutations are major contributors to human disability and illness. Although by definition, a rare genetic disease affects fewer than 1 in 2000 people (Europe) or fewer than 200 000 people in the USA (1), such diseases are collectively common and pose a significant medical, societal and economic cost (2, 3) . A recent Italian study found that rare diseases explain 4.2% of the general population years of life lost compared with 1.2% attributable to infectious diseases and 2.6% to diabetes mellitus (4) . In the past 10 years, rare disease gene discovery has increased significantly, outpacing the development of rare disease therapeutics (5) . The relatively slow development rate of rare genetic disease therapies can in part be attributed to lengthy, costly drug development including an increasingly inefficient drug approval process (6) . Although economic incentives from governments and rare disease patient groups have prompted an increased interest in developing rare disease therapeutics (7) , the gap continues to grow. Furthermore, even when developed, most rare disease drugs are prohibitively expensive (8, 9 ). An alternative to traditional rare disease drug development is to, at roughly one tenth the cost and at least twice the speed (10) , repurpose one of the growing number of clinically approved drugs (11) .
When rare diseases are viewed as disorders of gene/protein dosage, one credible strategy for drug repurposing focuses on the off-target impact of pharmaceuticals on disease modifying transcript (and thus protein) levels (12, 13) . This could be the upregulation of mutated recessive disease genes encoding proteins with residual enzymatic activity (and appropriate subcellular localization), of paralogous genes that are sequentially alike, and that functionally recapitulate mutated recessive disease genes, or of genes that cause disease when haploinsufficient. Conversely, the downregulation of mutated dominant genes which confer a gain of pathologic function or of genes that cause disease when present in increased number, may have clinical utility (14) . Therefore, clinic-tested drugs that modulate disease gene/protein levels may be effective in treating rare genetic diseases. We recently published a comparison of three methods of screening for promising clinic-ready drugrare disease gene interactions, establishing their relative yields and validation rates (i.e. whether in vitro modulation of transcripts correlated with protein levels). The two computational and one fibroblast-based screens analyzed $26 000 and $23 000 interactions, respectively, and resulted in the identification of a number of interactions which validated in vitro (13) .
To identify drug-gene interactions that may be useful for treating rare neurogenetic diseases, we conducted RNA sequencing (RNAseq)-based transcriptome profiling of mouse primary cerebrocortical cultures treated with 218 blood-brain barrier (BBB) penetrant clinic-ready drugs. The resulting dataset was then queried for upregulation of transcripts encoded by neurogenetic disease genes. Positive drug-gene interactions were assessed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to verify mRNA induction in vitro and further investigated in wild-type mice and rats was performed. These investigations have identified a link between thyroid hormone (TH) and upregulation of the peripheral myelin protein 22 (Pmp22) (15) , haploinsufficiency of which causes the rare hereditary neuropathy with liability to pressure palsies (HNPP). We have also developed an open-access application (the Neuron Screen database) permitting the search of our drug screen differential expression (DE) dataset to assist those studying neurogenetic and other neurologic diseases to identify similar drug-neurogenetic disease gene interactions.
Results

Mouse cerebrocortical culture model
To generate mammalian central nervous system transcriptomic profiles elicited by clinic-ready drugs (16, 17) , cortices of filial 1 offspring of an FVBN Â C3B6F1 cross at embryonic day 16.5 (E16.5) were pooled, triturated and cultured in monolayer. This triple hybrid (3H) mouse strain was created from three phylogenetically dissimilar strains (Jackson Labs) (18) to minimize the transcriptional bias of inbred mice (19) and model the comparatively more diverse genetics of most human populations (16) . To evaluate the cell type composition and neuronal synaptic maturity of these 3H cultures, immunofluorescence (IF) staining and electrophysiologic recordings were undertaken at day in vitro 21 (DIV21) (20, 21) .
Staining of the 3H cultures for neuron-specific MAP2 and astrocyte-specific ALDH1L1 showed roughly equal numbers of neurons and astrocytes (Fig. 1A) consistent with recent estimates of human cortex glial-to-neuron ratio (GNR) (22) and rat cortical cultures (20) . The 3H cultures also contained a variety of GABAergic interneurons as evidenced by staining for neuronal nitric oxide synthase (nNOS), parvalbumin and calretinin (Fig. 1B) . Staining for the microglia marker IBA1 and the endothelial marker VE-cadherin was negative. Cortical neuron synaptic maturity was confirmed by the punctate staining pattern of synaptic markers vesicular glutamate transporter (vGLUT) and vesicular GABA transporter (vGAT) (Fig. 1C) . Microelectrode array (MEA) recordings of 3H cultures at three stages of maturation demonstrated an increased frequency and synchrony of synaptic depolarizations at DIV21 also reflecting relative electrophysiologic maturity (Fig. 1D) . The three GABAergic interneuron subtypes detected by IF analysis (23, 24) , the mature cortical synapses reflected by vGAT and vGLUT punctate staining (20) , and the highly synchronous firing on MEAs characteristic of full cortical network maturity (25) all support the physiologic relevance of the 3H cortical culture system.
RNAseq drug screen
For the Neuron Screen, two hundred and seven drugs were selected from the Screen-Well FDA approved drug library v2 (Enzo Life Sciences) using three criteria: published reports of BBB penetrance, comparative safety consistent with long-term use and oral bioavailability. Another 11 Pfizer shelved phase II compounds were also included in the screen and 9 vehicle controls as well. The drugs used in the screen represent 80 therapeutic classes (Supplementary Material, Fig. S1 ).
After individual treatment of 3H cultures for 8 h (drug or vehicle), complementary DNA (cDNA) libraries, constructed from the poly-A fraction of total RNA extracted from drug and control treated 3H cultures, were sequenced, analyzed and organized to establish a transcriptome-wide DE dataset representing all 227 sequenced libraries. For each sample, gene expression for $14 000 genes with cpm >1 was normalized against the average of all conditions. Given that the screen was performed as a single replicate, the expression of a given gene across all samples served as the background to represent unaffected expression distributions. Robust z-scores and adjusted P-values (P-adj) for each potential drug-gene interaction were generated, with DE being defined as P-adj <0.05.
Quality control analysis revealed that more than 99% of the transcripts in the dataset were poly-adenylated (Supplementary Material, Table S1 ). An average of 114 genes were modulated in the drug treatment group compared with 12 in the control treatment group (Fig. 2A) ; in contrast the median number of responsive genes was roughly equal (21 and 22, respectively) indicating that most of the drugs modulated a small proportion of the neuronal transcriptome. The twenty-one (10%) strongest perturbagens and associated number of differentially expressed genes (DEGs) are shown in Figure 2B ; the top 5 drugs (fenofibrate, nilotinib, ciprofibrate, aminophylline and diflunisal) modulating >1000 genes each. Principal component analysis (PCA) of gene expression for the 227 libraries revealed no shared principal components underlying a large portion of the gene expression variance for most drugs assayed (Supplementary Material, Fig. S2 ), suggesting a diverse set of transcriptomic responses. However, the libraries for several of the top perturbagens (i.e. fenofibrate, nilotinib, diflunisal, ciprofibrate) diverge from the other drug and vehicle-treated libraries. Furthermore, DAVID Functional Annotation Tool was used to conduct enrichment analysis of biologic processes or cellular components (CC) for DEGs from the top five drugs (26, 27) ; 'endoplasmic reticulum (ER) stress', 'apoptosis signaling in response to ER stress', and 'cell cycle arrest' were overrepresented for the upregulated genes while the downregulated genes were enriched for 'CC of post-synaptic membranes' and 'ion transport'.
Validation of RNAseq data
Bioinformatic analyses and cellular toxicity studies were next used to explore the reliability of the Neuron Screen DE data. The upstream regulator analysis (URA) function of ingenuity pathway analysis (IPA) (28) was used to identify agents most likely to elicit the transcriptome signatures of four Neuron Screen agents from two well-characterized drug classes; thyroid analogs [liothyronine (T3) and levothyroxine (T4)] and corticosteroids [DEX and betamethasone (BMZ)]. This revealed both significant within class overlap as well as identifying L-triiodothyronine (structurally identical to T3) and three different steroids (DEX, corticosterone and fluticasone) as the upstream regulators of the thyroid analog and corticosteroid class profiles, respectively ( Fig. 3) , attesting to the validity of our dataset.
Dose dependent toxicity of four of the top transcriptionally active molecules was next assessed using the lactate dehydrogenase (LDH) assay. At the doses used for the Neuron Screen, only fenofibrate (the top transcriptional modulator in the screen) led to a statistically significant increase in cell death after 14-h treatment (Supplementary Material, Fig. S4 ). Despite this observation, for reasons outlined in the discussion, we believe the fenofibrate elicited transcriptome may have some utility; nonetheless, the drug-gene hits identified with this compound were not further explored.
Investigation of neuron screen drug-gene hits
To identify transcript-modulating repurposing candidates for rare neurogenetic diseases, we sought drugs that upregulate Table S2 ). Thirty-two drug-gene interactions were identified in this fashion (Fig. 4A) ; these treatments were repeated in 3H cortical cultures under the screen conditions followed by qRT-PCR measurement of the specific mRNA. Six of the 32 interactions, $20%, validated (P < 0.05); half of these [nilotinib (10 lM)-Sacs, aminophylline (90 lM)-Aldh18a1 and T4 (0.2 lM)-Pmp22] conferred a $2-fold average upregulation of transcript ( Fig. 4B-F) .
The TH-Pmp22 interaction was further assessed in vitro and in vivo; given PMP22 protein is primarily expressed in myelinating Schwann cells, primary rat dorsal root ganglion (DRG) cultures were treated with T3 analog of TH (and not T4, as Deiodinase II that converts T4 to the more active T3 is not consistently expressed in the peripheral nervous system) (29, 30) . IF staining of DIV28 DRG cultures showed highly intertwined neurons (b-III tubulin positive) indicative of a mature DRG culture (Supplementary Material, Fig. S5 ). Cultures were treated for three weeks with T3 (10, 31.6, 100 nM); qRT-PCR analysis showed $50% increase in Pmp22 mRNA for all treatments (Fig. 5A) . Although IF staining of PMP22 was too faint to detect expression in myelin, the presence of cells with perinuclear staining pattern of PMP22 typical of non-myelinating Schwann cells was observed (31) (Fig. 5C-F) . Signal intensity of PMP22 could not be rigorously quantitated owing to high background signal, but quantification of total PMP22-stained cells showed a trend toward upregulation for all three T3 doses (Fig. 5B) .
The drug-gene pairings that transcriptionally validated in cell culture (nilotinib-Sacs, aminophylline-Aldh18a1, DEXHsd17b4, TH-Pmp22 and diflunisal-Slc6a8) were next tested in wild-type mice (C57BL6) or rats (Sprague-Dawley) with intraperitoneal injections or oral gavage doses equivalent to the highest tolerated in humans (Supplementary Material, Methods). qRT-PCR-based measurement of cortical transcript for the five drug-gene pairings studied, identified an increase for the TH-Pmp22 pairing; Sprague-Dawley rats dosed with 300 lg T4 showed a $25% upregulation of Pmp22 in cortex (Fig. 6A) . Furthermore, three well-characterized TH-responsive genes-i.e. Hairless (Hr), Sonic hedgehog (Shh) and Semaphorin 7a (Sema7a) (32, 33) that were upregulated in 3H cultures in response to T4 (RNAseq data), were also upregulated (!2-fold) in the cortex of T4-treated rats (Fig. 6B ).
Drug screen database
Using the R-studio Shiny package, we have created a userfriendly interactive website database to enable researchers to mine the Neuron Screen data from the 218 drug treatment expression profiles ($3 M drug-gene interactions), for interactions of their choice. The 'Primary mouse cortical culture RNAseq drug screen database' can be searched by drug, gene symbol or Ensembl gene ID, and the z-score cutoff adjusted for output. The database provides the user with the identities of the interacting drugs or genes (depending on their query), the dose of the drugs and the associated z-score and adjusted P-value of the drug-gene interactions (Fig. 7) . It can be freely accessed at 'bigbear.med.uottawa.ca:1000'.
Discussion
There exists a growing gap between the number of molecularly defined rare diseases and effective therapies for these conditions. One potentially generalizable means of addressing this problem is the pharmacologic modulation of specific disease related genes, redressing the pathogenic dysregulated protein levels (and activity), an approach that has been previously proposed for a number of rare genetic diseases. The observation 70 years ago of the beneficial effect of persistent fetal gamma hemoglobin on sickle cell disease has led to long standing efforts to induce this hemoglobin beta paralog for diverse hemoglobinopathies (34) . The upregulation of paralogs for Duchenne muscular dystrophy (35) and X-linked adrenoleukodystrophy (36) have also been proposed while induction of SMN2 for spinal muscular atrophy has become a clinical reality (37) . Pharmacologic gene induction has also been suggested for haploinsufficient disorders; estrogen treatment of the epistaxis associated with hereditary hemorrhagic telangiectasia (38) as well as a number of compounds demonstrating induction of GRN to treat frontotemporal dementia (39) . To broaden this approach to additional neurogenetic conditions, we have performed system wide RNAseq analysis of a primary mixed neuronal glial cell system cultured in the presence of 218 drugs and then studied specific transcripts encoded by rare disease related genes as a proxy for protein. A 1:1 GNR, three GABAergic interneuron subtypes and the highly synchronous firing on MEAs characteristic of full cortical network maturity (25) all support the physiologic relevance of the 3H cortical culture system.
Our study of 218 drug-induced neuronal transcriptomes revealed that 5 agents collectively account for almost half of the DE genes (in descending order: fenofibrate, nilotinib, ciprofibrate, aminophylline and diflunisal). PCA revealed that four of these drugs induced gene expression patterns that deviated noticeably from the primary gene expression cluster. Furthermore, bioinformatic analysis (using DAVID) of genes upregulated by all 5 drugs revealed 21% enrichment in genes associated with ER stress (40) (41) (42) , intrinsic apoptosis signaling, and cell cycle arrest while similar analysis of downregulated genes revealed over 50% are involved in post synaptic membrane and ion transport functions. However, only fenofibrate (80 lM) led to overt cytotoxicity in cortical neurons. Similarly, the top five perturbagens had only 57 responsive genes (42 upregulated and 15 downregulated) in common suggesting that simple cell stress was not the reason for most of the observed DE. In keeping with this, a recent study has documented altered expression of $4000 transcripts, close to the number of DE genes in our study, in prefrontal cortex of fenofibrate-treated mice (43) . Furthermore, other reports both in neuronal and non-neuronal cells have also shown broad transcriptomic impact of these drugs with no reported cytotoxicity (43) (44) (45) . Interestingly, as potent neuronal perturbagens as these agents are, they rank no higher than 71st percentile (nilotinib) and as low as 17th percentile (ciprofibrate) in the connectivity map ranking of perturbagens employing a number of immortalized cell lines (46) . Thus, ER stress gene activation in the Neuron Screen may highlight the difference in sensitivity that exists between primary neuron cells and immortalized cancer cells.
One method of transcriptomic DE gene data validation in an experimental system is identifying an anticipated (e.g. HDAC inhibitor) expression signature as a positive control (47) . In this regard, highly similar transcriptional effects of both two TH analogs and two corticosteroids as well as aligning with the published transcriptomic impact of both drug classes was observed, attesting to the validity of our screen. Furthermore, the validation of $20% mRNA inducing drug gene interactions (Supplementary Material, Fig. S4 ) is double that recently documented for a similar fibroblast screen and four times that identified from connectivity map data (13) . Although the 32 hits were identified with a P-adj <0.05, only those with P-adj <0.01 validated at the transcript level; moreover, for hits with a P-adj <0.01, the validation rate increased by 50% with no decrease in statistical power suggesting that the more stringent statistical cutoff might be optimal when analyzing the Neuron Screen data.
The effect of TH on Pmp22 gene expression is a novel finding and one that requires further investigation. Of the five hits that validated in 3H cortical cultures, T4-Pmp22 drug-gene combination was the most promising, leading to a statistically significant and potentially therapeutically relevant 25% upregulation in whole animal studies (14) . This was accompanied by a >2-fold upregulation of three TH-responsive genes, reflecting supra-physiologic cortical levels of TH in treated rats (48) . Given HNPP chiefly impacts the PNS, we next assessed the effect of TH in rat PNS cultures; T3 (100 nM) led to a $50% upregulation of Pmp22 transcript and an increase in PMP22 stained cells. Interestingly, there appears to be a plateau effect of TH on Pmp22 as similar gene expression was observed across the T3 dose-curve, potentially representing saturation of the gene's TH receptor binding elements (49) .
Although TH has not been previously related to PMP22 expression, a recent case report detailed HNPP symptoms worsening with a diagnosis of hypothyroidism and markedly improved with TH treatment (50) . Exploration of the impact of TH on haploinsufficient Pmp22 mice with HNPP-like disruption of Transcriptome data for T3, T4, DEX and BMZ treated cultures was assessed using IPA to identify upstream regulators (agents which are the most likely to lead to the observed signature) resulting in the identification of (A) L-triiodothyronine (structurally identical to T3) for both the T3 and T4 profiles and (B) three different steroid compounds for the DEX and BMZ signatures; DEX itself, corticosterone and the halogenated steroid, fluticasone.
PNS myelination (51) may be of value; ultimately HNPP clinical trials employing thyromimetic compounds (thus avoiding iatrogenic hyperthyroidism) as has been proposed for the treatment of X-ALD (36,52) may be an option. Conversely clinicians may want to proceed cautiously when considering thyroid therapy for patients with Charcot-Marie-Tooth disease type 1A, a condition caused by PMP22 gene duplication and resulting pathogenic overexpression of the protein (15) .
In conclusion, the demonstration of T4 mediated Pmp22 upregulation in rat cortex serves as a validation of our primary cerebrocortical culture and screen as a means of identifying clinically relevant drug-gene interactions as a prelude to the potential repurposing of drugs for rare neurogenetic diseases. In addition to modulation of individual rare disease-associated transcripts, transcriptomal profiles can also serve as therapeutic targets (53, 54) . Whether through identifying drugs that either impact individual genes or generate neuronal transcriptomes that are orthogonal to disease transcriptional profiles (55) , the Neuron Screen database will enable the identification of novel therapeutic leads for rare neurogenetic diseases as well as serve as a valuable resource for the broader neuroscience community. (n ¼ 7) upregulate Pmp22; (F) 0.5 lM DEX (n ¼ 6) and 0.4 lM BMZ (n ¼ 7) upregulate Hsd17b4. Target gene expression was normalized against Gapdh and shown as treated over vehicle (0.2% DMSO) expression. Statistical analysis was performed by student's two-tailed unpaired t-test *P < 0.05, ***P < 0.001.
Materials and Methods
Animal care and treatments
All protocols were approved by the Animal Care and Veterinary Services (ACVS) and Ethics board of the University of Ottawa. The female FVB/N and male C3B6F1 mice used for generating embryos for cerebrocortical cultures were supplied by Jackson Labs. Animals were housed in triplicate and given food and water ad libitum. For in vivo drug studies, male C57BL6 mice (8 weeks old) and male Sprague-Dawley rats (8 weeks old) were obtained from Charles River. Mice and rats were treated daily as per the details found in Supplementary Material, Note S1. T4 treatments were performed in rats whereas mice were used for the other four drugs [aminophylline, dexamethasone (DEX), 
Tissue culture
Mouse 3H cortical cultures Female FVB/N mice were crossed with male C3B6F1 to create 3H embryos. Female and male mice were singly housed and given food and water ad libitum before and after initiation of timed mating. Precise timed mating was verified by the presence of a vaginal plug (embryonic day 0.5) by experienced animal technicians. Dams were sacrificed at E16.5 by isoflurance and cervical dislocation. Neuronal culture was performed as previously described (20) . Briefly, cortex was isolated from E16.5 embryos and cultured for 21 days on 6-and 96-well poly-D-lysine (PDL, 50 lg/ml) coated polystyrene plates and maintained in Neurobasal medium containing B27 supplement (2%), GlutaMAX (2%), 100 IU/ml penicillin and 100 lg/ml streptomycin. Plating densities were 1E6 and 6E4 cells per well for the 6-and 96-well plates, respectively. Further 3H tissue culture details are provided in Supplementary Material, Note S2.
Dorsal root ganglion
Cryopreserved rat DRGs were purchased from QBM Cell Science. DRGs were grown on 12-well (60 000 cells/well) and 96-well (5000 cells/well) plates coated overnight with PDL (50 lg/ml) and subsequently with laminin (20 lg/ml) for 1 h at 37 C. DRG cultures were seeded in Neurobasal medium containing B27 supplement (2%), GlutaMAX (2%), 100 IU/ml penicillin, 100 lg/ml streptomycin and 50 ng/ml nerve growth factor. A 50% media change was performed after 4 days, and subsequent 75% media changes were performed every 2-3 days. After 7 days in vitro, media was supplemented with 50 lg/ml ascorbic acid (AA) to induce myelination and treated with DMSO (0.1%) or T3 (10, 31.6, 100 nM) (56) . Cultures were maintained for 21 or 28 days in vitro after addition of AA and T3 with 75% media changes containing fresh AA þDMSO or AA þT3 every 2-3 days until harvesting.
Immunofluorescence IF staining was performed on cortical cultures (DIV21) in 96-well polystyrene plates. Cells were fixed in 4% formaldehyde containing 7% (v/v) picric acid for 20 min at room temperature (20) . Primary antibody incubation was performed using the vibration technique (57) . Details on IF staining and antibodies are provided in Supplementary Material, Note S3.
Neuronal network recordings
Network extracellular electrophysiologic recordings of cortical cultures were performed with an MEA system from MultiChannel Systems. Triple hybrid mouse cortical cultures were grown on PDL (50 lg/ml) and laminin (20 lg/ml) coated glass MEAs and recordings were obtained as described by Schock et al. (20) . Recordings were taken at DIV7, DIV15 and DIV21 and performed for a total of 300 s on each day from all 60 electrodes on the MEA. Analysis of burst frequency and synchrony was done by using the software SpAnNer [as outlined by Otto et al. (58) 
Bioinformatics
DE analysis
Fastq files from Illumina sequencing were aligned to the mm10 reference genome using Star (version 2.4.0). All fastq files were validated to be single-stranded and reverse-stranded. Read counts were summarized to gene-level by the feature count module of Subread package (version 1.4.6). All samples passed quality control based on post-alignment metrics using RSeQC (version 2.6.1). Genes that had raw counts ¼0 and/or counts per million (cpm) <1 across all 227 samples were excluded from the final results. Normalization was performed using limma/EdgeR package (version 3.10.5). Briefly, two levels of normalization were performed to adjust for: (i) library size; (ii) mean-variance heteroscedasticity. The trimmed mean of M-values method was used to calculate a weighted trimmed mean across all samples (61) . Mean-variance relationship was estimated by the Voom module. PCA was calculated to check for systemic bias across samples. The top four principle components were removed, and the resultant residuals were used for subsequent analysis. Robust z-scores were calculated for each gene. P-values were calculated using two-tailed test and multiple-testing adjusted by the Benjamini Hochberg method (62) . Drug-induced differential gene expression was defined by an adjusted P-value (P-adj.) <0.05.
Ingenuity pathway analysis
The transcriptome-wide DE datasets from T4, T3, BMZ and DEX were entered individually into the IPA software (Qiagen Bioinformatics). The two metrics of DE that were entered were 'z-score' and 'P-adj', and data entered were limited to an absolute z-score greater >3. Each dataset was then individually analyzed by IPA using default settings on the analysis tool. After analysis, the IPA comparison tool was used to determine the similarities between the transcriptional perturbations caused by levothyroxine (T4) and T3 and by the perturbations caused by DEX and BMZ. Comparison between drugs in each class was done by using the URA heatmap function.
Quantitative RT-PCR qRT-PCR was used to investigate the validity of hits from the Neuron Screen in cortical cultures, in DRGs, and in whole mouse and rat experiments. Gene-specific primers were designed for each gene of interest and Gapdh & Hprt1 were used as housekeeping genes. Primers available upon request. Complete qRT-PCR protocol is provided in Supplementary Material, Note S6.
LDH assay
The CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) was used to determine the cellular toxicity of five Neuron Screen drugs on the 3H cortical culture system (96-well format cultures). Cultures at DIV21 were treated with half-log doses of fenofibrate, nilotinib, aminophylline, diflunisal for 8 or 14 h. The LDH assay was performed as per the kit specifications. Absorbance at 490 nm was used measure LDH in the culture media, on the SpectraMax 340 Microplate Reader (Molecular Devices). Media from living treated and non-treated cells was normalized to media from cells after complete cell death by freeze-thaw.
Statistical analysis. Statistical analysis of single pair-wise comparisons was calculated by unpaired two-tailed t-test with 95% CI, and the null hypothesis was rejected at P < 0.05. For multiple pair-wise comparisons performed by qRT-PCR, one-way ANOVA was performed with Tukey post hoc test and 95% CI with null hypothesis rejected at P < 0.05. Statistics for DE-RNAseq are summarized in the Differential analysis section.
RNAseq data deposition
The raw sequencing fastq files generated by RNAseq and analyzed to create the Shinny DE database are available from the Gene Expression Omnibus (GEO) database (accession number GSE110256).
Supplementary Material
Supplementary Material is available at HMG online.
